We are live on ! Find out more
MA

MYDA Advisors Portfolio holdings

AUM $608M
1-Year Est. Return 77.08%
This Fund
S&P 500
This Quarter Est. Return
+1.96%
1 Year Est. Return
+77.08%
3 Year Est. Return
+189.24%
5 Year Est. Return
+248.06%
10 Year Est. Return
AUM
$213M
AUM Growth
-$145M
Cap. Flow
-$140M
Cap. Flow %
-65.54%
Top 10 Hldgs %
33.84%
Holding
249
New
48
Increased
13
Reduced
49
Closed
93

Sector Composition

Rank Sector Weight
1 Financials 31.85%
2 Technology 12.56%
3 Consumer Discretionary 8.7%
4 Industrials 6.54%
5 Communication Services 6.25%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
NXDR
126
Nextdoor Holdings
NXDR
$835M
$140K 0.07%
50,000
+20,000
+67% +$65.9K
AFMD
127
DELISTED
Affimed
AFMD
$134K 0.06%
6,500
CFMS
128
DELISTED
Conformis, Inc. Common Stock
CFMS
$133K 0.06%
+27,896
New +$194K
MARA icon
129
Marathon Digital Holdings
MARA
$4.62B
$129K 0.06%
+12,000
New +$142K
RKLB icon
130
Rocket Lab Corp
RKLB
$39.9B
$122K 0.06%
+30,000
New +$148K
ORGNW
131
DELISTED
Origin Materials Inc Warrants
ORGNW
$121K 0.06%
115,347
-38,112
-25% -$45.3K
VLD
132
DELISTED
Velo3D, Inc.
VLD
$118K 0.06%
+857
New +$111K
EVLV icon
133
Evolv Technologies
EVLV
$943M
$106K 0.05%
+50,000
New +$130K
LICY
134
CALL
DELISTED
Li-Cycle Holdings Corp.
LICY
$106K 0.05%
2,500
IRON icon
135
Disc Medicine
IRON
$2.83B
$103K 0.05%
2,100
+1,433
+215% +$67.6K
LAAA
136
DELISTED
Lakeshore Acquisition I Corp. Ordinary Shares
LAAA
$101K 0.05%
10,000
-166,000
-94% -$1.67M
VNTR
137
DELISTED
Venator Materials PLC
VNTR
$96K 0.05%
108,688
-61,749
-36% -$104K
ELVN icon
138
Enliven Therapeutics
ELVN
$3.78B
$91K 0.04%
+10,000
New +$59K
ASLN
139
DELISTED
ASLAN Pharmaceuticals Limited American Depositary Shares
ASLN
$90K 0.04%
3,750
STRY
140
DELISTED
Starry Group Holdings, Inc.
STRY
$89K 0.04%
+60,000
New +$171K
DNTH icon
141
Dianthus Therapeutics
DNTH
$5.68B
$85K 0.04%
3,750
FLACW
142
DELISTED
Frazier Lifesciences Acquisition Corporation Warrant
FLACW
$77K 0.04%
101,999
-27,801
-21% -$17.6K
ASTLW icon
143
Algoma Steel Group Warrant
ASTLW
$387K
$66K 0.03%
69,150
-80,850
-54% -$145K
BGRY
144
DELISTED
Berkshire Grey, Inc. Class A Common Stock
BGRY
$53K 0.02%
+31,050
New +$62K
LUXAW
145
DELISTED
Lux Health Tech Acquisition Corp. Warrants
LUXAW
$44K 0.02%
326,000
-14,509
-4% -$2.05K
RNWWW
146
ReNew Energy Global PLC Warrant
RNWWW
$59.3K
$33K 0.02%
31,300
LAAAW
147
DELISTED
Lakeshore Acquisition I Corp. Warrant
LAAAW
$26K 0.01%
131,250
RKLY
148
CALL
DELISTED
Rockley Photonics Holdings Limited
RKLY
$21K 0.01%
+30,000
New +$51.2K
TINV.WS
149
DELISTED
Tiga Acquisition Corp. Warrants, each warrant exercisable for one Class A ordinary share at an exercise price of $11.50 per share
TINV.WS
$21K 0.01%
30,000
-8,800
-23% -$6.03K
MREO
150
Mereo BioPharma
MREO
$45.9M
$19K 0.01%
21,502
-8,498
-28% -$10.4K

Similar funds

MYDA Advisors's Q3 2022 Portfolio in Review

As of Q3 2022, MYDA Advisors held 249 positions worth $213M, down 40% from $358M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

MYDA Advisors withdrew a net $140M in Q3 2022, closing 93 positions and reducing 49 holdings. Its most notable exit was iShares Expanded Tech-Software Sector ETF, an estimated $3.5M position sold in full.

By sector, the portfolio is most concentrated in Financials at 32% of assets, up from 24% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, MYDA Advisors opened a new position in Adobe worth $5.5M.

  • MYDA Advisors's largest Q3 2022 buy was Adobe: 20,000 shares worth $5.5M.
  • MYDA Advisors added most to Enovix in Q3 2022, an estimated $1.86M increase.
  • MYDA Advisors's biggest Q3 2022 reduction was Marriott International, cutting an estimated $11.5M.
  • MYDA Advisors fully exited iShares Expanded Tech-Software Sector ETF in Q3 2022, selling an estimated $3.5M.
  • MYDA Advisors's ten largest holdings make up 34% of its $213M portfolio in Q3 2022.
  • MYDA Advisors opened 48 new positions and closed 93 in Q3 2022.
  • MYDA Advisors's portfolio value fell 40% quarter-over-quarter to $213M.

Based on MYDA Advisors's 13F filing for Q3 2022, filed 10 Nov 2022.